Biotricity Q2 FY2022 revenue $1.81M (+143% YoY); net loss $11M includes $5.46M one-time costs

BIOTRICITY INC.

Revenue of $1.81 million, up 143% year-over-year; gross margin 62%.
Net loss $11.0M ($0.256/sh); adjusted net loss $5.2M ($0.128/sh) excluding $5.46M Nasdaq up-listing costs.
Ended quarter with $11.7 million cash, strongest balance sheet ever.
Announced Biokit personal medical device kit for home-use cardiac monitoring; commercial launch planned Q1 2022.
Revenue impacted by hurricanes and COVID clinic closures in southern US; expects recapture in subsequent months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.